JPWO2022014680A1 - - Google Patents

Info

Publication number
JPWO2022014680A1
JPWO2022014680A1 JP2022536446A JP2022536446A JPWO2022014680A1 JP WO2022014680 A1 JPWO2022014680 A1 JP WO2022014680A1 JP 2022536446 A JP2022536446 A JP 2022536446A JP 2022536446 A JP2022536446 A JP 2022536446A JP WO2022014680 A1 JPWO2022014680 A1 JP WO2022014680A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536446A
Other languages
Japanese (ja)
Other versions
JPWO2022014680A5 (cg-RX-API-DMAC7.html
JP7190612B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022014680A1 publication Critical patent/JPWO2022014680A1/ja
Application granted granted Critical
Publication of JP7190612B2 publication Critical patent/JP7190612B2/ja
Publication of JPWO2022014680A5 publication Critical patent/JPWO2022014680A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pain & Pain Management (AREA)
JP2022536446A 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途 Active JP7190612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020122864 2020-07-17
JP2020122864 2020-07-17
PCT/JP2021/026649 WO2022014680A1 (ja) 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途

Publications (3)

Publication Number Publication Date
JPWO2022014680A1 true JPWO2022014680A1 (cg-RX-API-DMAC7.html) 2022-01-20
JP7190612B2 JP7190612B2 (ja) 2022-12-15
JPWO2022014680A5 JPWO2022014680A5 (cg-RX-API-DMAC7.html) 2022-12-16

Family

ID=79291962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536446A Active JP7190612B2 (ja) 2020-07-17 2021-07-15 置換ピペリジン化合物及びその用途

Country Status (19)

Country Link
US (1) US11479552B2 (cg-RX-API-DMAC7.html)
EP (1) EP4151277A4 (cg-RX-API-DMAC7.html)
JP (1) JP7190612B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040953A (cg-RX-API-DMAC7.html)
CN (3) CN115884971B (cg-RX-API-DMAC7.html)
AR (1) AR122973A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021308053A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026161A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187835A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003666A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022018446A2 (cg-RX-API-DMAC7.html)
IL (1) IL299125B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016388A (cg-RX-API-DMAC7.html)
PE (1) PE20231103A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022553488A1 (cg-RX-API-DMAC7.html)
TW (1) TWI888599B (cg-RX-API-DMAC7.html)
UA (1) UA129636C2 (cg-RX-API-DMAC7.html)
WO (1) WO2022014680A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213562B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4065585T3 (da) 2019-11-25 2025-09-08 Alkermes Inc Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7591592B2 (ja) * 2022-01-14 2024-11-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 置換ピペリジン化合物を含有する医薬
CN118451076A (zh) * 2022-01-14 2024-08-06 卫材R&D管理有限公司 经取代的哌啶化合物的晶体、经取代的哌啶化合物的盐及其晶体
TW202423404A (zh) * 2022-10-07 2024-06-16 日商橘生藥品工業股份有限公司 環戊烷化合物
TW202432109A (zh) * 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
KR20250112793A (ko) 2022-12-16 2025-07-24 다이이찌 산쿄 가부시키가이샤 2-아자비시클로[3.1.1]헵탄 화합물
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
JP2008517032A (ja) * 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP2016512536A (ja) * 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ.ベー. 置換した7−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG34208A1 (en) 1995-03-01 1996-12-06 Guy Andrew Vaz Blast and fragment resistant polyurethane boot sole for safety footwear
WO1996034877A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6159605A (en) 1997-02-18 2000-12-12 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Ink-jet recording sheet
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
KR100327888B1 (ko) 1999-07-14 2002-03-09 정숭렬 도로포장 파손촉진 시험장치의 무선제어 시스템
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
JP2008517032A (ja) * 2004-10-20 2008-05-22 ノイロサーチ アクティーゼルスカブ 新規なジアザ二環式アリール誘導体及びその医薬用途
JP2016512536A (ja) * 2013-03-13 2016-04-28 ヤンセン ファーマシューティカ エヌ.ベー. 置換した7−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用

Also Published As

Publication number Publication date
CL2022003666A1 (es) 2023-05-26
CN119235864A (zh) 2025-01-03
US20220017517A1 (en) 2022-01-20
AR122973A1 (es) 2022-10-19
EP4151277A1 (en) 2023-03-22
CN119258067A (zh) 2025-01-07
CN115884971A (zh) 2023-03-31
UA129636C2 (uk) 2025-06-18
MX2022016388A (es) 2023-01-30
CA3187835A1 (en) 2022-01-20
KR20230040953A (ko) 2023-03-23
IL299125A (en) 2023-02-01
BR112022026161A2 (pt) 2023-01-31
PH12022553488A1 (en) 2024-04-22
US11479552B2 (en) 2022-10-25
WO2022014680A1 (ja) 2022-01-20
CN115884971B (zh) 2024-11-05
TWI888599B (zh) 2025-07-01
IL299125B1 (en) 2025-11-01
EP4151277A4 (en) 2024-06-26
PE20231103A1 (es) 2023-07-19
AU2021308053A1 (en) 2023-02-02
JP7190612B2 (ja) 2022-12-15
TW202216705A (zh) 2022-05-01
CO2022018446A2 (es) 2023-03-07
ZA202213562B (en) 2023-10-25

Similar Documents

Publication Publication Date Title
BR112023005462A2 (cg-RX-API-DMAC7.html)
BR112023012656A2 (cg-RX-API-DMAC7.html)
BR112021014123A2 (cg-RX-API-DMAC7.html)
BR112023009656A2 (cg-RX-API-DMAC7.html)
BR112022009896A2 (cg-RX-API-DMAC7.html)
BR112023008622A2 (cg-RX-API-DMAC7.html)
BR112022024743A2 (cg-RX-API-DMAC7.html)
BR112022026905A2 (cg-RX-API-DMAC7.html)
BR112023011738A2 (cg-RX-API-DMAC7.html)
BR112023004146A2 (cg-RX-API-DMAC7.html)
BR112023006729A2 (cg-RX-API-DMAC7.html)
BR102021018859A2 (cg-RX-API-DMAC7.html)
BR102021015500A2 (cg-RX-API-DMAC7.html)
BR112021017747A2 (cg-RX-API-DMAC7.html)
BR102021007058A2 (cg-RX-API-DMAC7.html)
BR102020022030A2 (cg-RX-API-DMAC7.html)
BR112023016292A2 (cg-RX-API-DMAC7.html)
BR112023011539A2 (cg-RX-API-DMAC7.html)
BR112023011610A2 (cg-RX-API-DMAC7.html)
BR112023008976A2 (cg-RX-API-DMAC7.html)
BR102021020147A2 (cg-RX-API-DMAC7.html)
BR102021018926A2 (cg-RX-API-DMAC7.html)
BR102021018167A2 (cg-RX-API-DMAC7.html)
BR102021017576A2 (cg-RX-API-DMAC7.html)
BR102021016837A2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221026

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221205

R150 Certificate of patent or registration of utility model

Ref document number: 7190612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250